跳转至内容
Merck
CN

880420P

Avanti

18:0 PEG350 PE

Avanti Polar Lipids 880420P, powder

登录查看公司和协议定价

别名:
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] (ammonium salt)
UNSPSC代码:
51191904
NACRES:
NA.25

形式

powder

包装

pkg of 1 × 25 mg (880420P-25mg)
pkg of 1 × 500 mg (880420P-500mg)

制造商/商品名称

Avanti Polar Lipids 880420P

运输

dry ice

储存温度

−20°C

SMILES字符串

[H][C@@](COP([O-])(OCCNC(OCCOCCOCCOCCOCCOCCOCCOC)=O)=O)(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O.[NH4+]

应用

18:0 PEG350 PE is suitable for liposome modification.

包装

30 mL Amber Wide Mouth Bottle with Screw Cap (880420P-500mg)
5 mL Clear Glass Sealed Ampule (880420P-25mg)

WGK

WGK 3

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo
Sieber S, et al.
Nanomedicine: Nanotechnology, Biology, and Medicine, 17, 82-93 (2019)
Sandro Sieber et al.
Nanomedicine : nanotechnology, biology, and medicine, 17, 82-93 (2019-01-20)
Macrophage recognition of nanoparticles is highly influenced by particle size and surface modification. Due to the lack of appropriate in vivo screening models, it is still challenging and time-consuming to characterize and optimize nanomedicines regarding this undesired clearance mechanism. Therefore
Liming Deng et al.
Biomaterials science, 8(3), 858-870 (2019-12-07)
Hypoxic resistance, photosensitizer toxicity, and target deficiency are major challenges strongly inhibiting the efficacy of clinical photodynamic therapy (PDT) in tumor treatment. To overcome these challenges, we synthesized IR780 and catalase co-loaded liposomes to form a tumor-targeted bio-nanoreactor (LIP-IR-CAT). The

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门